A copy of this work was available on the public web and has been preserved in the Wayback Machine. The capture dates from 2019; you can also visit the original URL.
The file type is
Purpose: To evaluate the effects of ritonavir, a potent inhibitor of CYP3A4, on the steady-state pharmacokinetics of imatinib. Experimental Design: Imatinib pharmacokinetics were evaluated in cancer patients receiving the drug for at least 2 months, after which ritonavir (600 mg) was administered daily for 3 days. Samples were obtained on the day before ritonavir (day1) and on the third day (day 4).The in vitro metabolism of imatinib with or without ritonavir and the effect of imatinib ondoi:10.1158/1078-0432.ccr-07-0346 pmid:18094422 fatcat:px7mu5ytzjhj7os2dmfyigenny